{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,11,23]],"date-time":"2025-11-23T06:13:37Z","timestamp":1763878417708,"version":"3.37.3"},"reference-count":45,"publisher":"FapUNIFESP (SciELO)","issue":"4","license":[{"start":{"date-parts":[[2020,12,1]],"date-time":"2020-12-01T00:00:00Z","timestamp":1606780800000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc\/4.0\/"},{"start":{"date-parts":[[2020,12,1]],"date-time":"2020-12-01T00:00:00Z","timestamp":1606780800000},"content-version":"am","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc\/4.0\/"},{"start":{"date-parts":[[2020,12,1]],"date-time":"2020-12-01T00:00:00Z","timestamp":1606780800000},"content-version":"tdm","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc\/4.0\/"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Arq. Gastroenterol."],"abstract":"<jats:p>ABSTRACT  BACKGROUND:  Lubiprostone is a type 2 chloride channel activator that has been shown to be efficacious and safe in the treatment for chronic constipation.  OBJECTIVE:  To systematically review randomized clinical trials (RCTs) assessing efficacy of lubiprostone for patients with chronic idiopathic constipation (CIC), irritable bowel syndrome with predominant constipation (IBS-C) and opioid-induced constipation (OIC).  METHODS:  Searches were conducted in PubMed, LILACS, Cochrane Collaboration Database, and Centre for Reviews and Dissemination. Lubiprostone RCTs reporting outcomes of spontaneous bowel movements (SBM) and abdominal pain or discomfort were deemed eligible. Meta-analysis was performed calculating risk ratios and 95% confidence intervals, using the Mantel-Haenszel method and random effects model.  RESULTS:  Searches yielded 109 records representing 93 non-duplicate publications, and 11 RCTs (978 CIC, 1,366 IBS-C, 1,300 OIC, total = 3,644) met inclusion criteria. Qualitative synthesis showed that for CIC patients, lubiprostone is superior to placebo in terms of SBM outcomes. Meta-analysis for CIC was feasible for full responder and SBM within 24h rates, indicating superiority of lubiprostone over placebo. For IBS-C, lubiprostone was significantly superior for all SBM outcomes in follow-ups ranging from 1 week-3 months. In terms of abdominal pain, lubiprostone provided significantly better symptoms relief, particularly after 1 month of treatment. For OIC, lubiprostone was more effective than placebo for both SBM and discomfort measures.  CONCLUSION:  Our findings demonstrated that lubiprostone is superior to placebo in terms of SBM frequency for CIC, IBS-C and OIC. In terms of abdominal symptoms, the most pronounced effect was seen for abdominal pain in IBS-C patients.<\/jats:p>","DOI":"10.1590\/s0004-2803.202000000-83","type":"journal-article","created":{"date-parts":[[2020,12,12]],"date-time":"2020-12-12T06:25:37Z","timestamp":1607754337000},"page":"498-506","source":"Crossref","is-referenced-by-count":11,"title":["Systematic review with meta-analysis: lubiprostone efficacy on the treatment of patients with constipation"],"prefix":"10.1590","volume":"57","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-5247-9477","authenticated-orcid":false,"given":"Maria do Carmo F","family":"PASSOS","sequence":"first","affiliation":[{"name":"Universidade Federal de Minas Gerais,  Brasil"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-7016-2879","authenticated-orcid":false,"given":"Maira Libertad Soligo","family":"TAKEMOTO","sequence":"additional","affiliation":[{"name":"ANOVA Consultoria em Sa\u00fade,  Brasil"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-6645-4097","authenticated-orcid":false,"given":"Gabriel Cyrillo","family":"CORRADINO","sequence":"additional","affiliation":[{"name":"Takeda Pharmaceuticals Brazil,  Brasil"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-8901-2600","authenticated-orcid":false,"given":"Luciana S","family":"GUEDES","sequence":"additional","affiliation":[{"name":"Takeda Pharmaceuticals Brazil,  Brasil"}],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"530","published-online":{"date-parts":[[2020,12]]},"reference":[{"key":"ref1","doi-asserted-by":"crossref","first-page":"3","DOI":"10.1016\/j.bpg.2010.12.010","article-title":"Epidemiology of constipation in children and adults: A systematic review","volume":"25","author":"Mugie SM","year":"2011","journal-title":"Best Pract Res Clin Gastroenterol"},{"key":"ref2","doi-asserted-by":"crossref","first-page":"1582","DOI":"10.1038\/ajg.2011.164","article-title":"Prevalence of, and risk factors for, chronic idiopathic constipation in the community: systematic review and meta-analysis","volume":"106","author":"Suares NC","year":"2011","journal-title":"Am J Gastroenterol"},{"key":"ref3","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1155\/2018\/5704627","article-title":"Incidence and health related quality of life of opioid-induced constipation in chronic noncancer pain patients: A Prospective Multicentre Cohort Study","volume":"2018","author":"Veiga DR","year":"2018","journal-title":"Pain Res Treat"},{"key":"ref4","doi-asserted-by":"crossref","first-page":"141","DOI":"10.1016\/j.gastrohep.2018.10.008","article-title":"A retrospective and prospective 12-month observational study of the socioeconomic burden of moderate to severe irritable bowel syndrome with constipation in Spain","volume":"42","author":"Mearin F","year":"2019","journal-title":"Gastroenterol Hepatol"},{"key":"ref5","doi-asserted-by":"crossref","first-page":"682","DOI":"10.1016\/j.clinre.2019.02.011","article-title":"Quality of life in 1870 patients with constipation and\/or fecal incontinence: constipation should not be underestimated","volume":"43","author":"Brochard C","year":"2019","journal-title":"Clin Res Hepatol Gastroenterol"},{"key":"ref6","doi-asserted-by":"crossref","first-page":"374","DOI":"10.1186\/1471-2458-14-374","article-title":"Cost savings of reduced constipation rates attributed to increased dietary fiber intakes: a decision-analytic model","volume":"14","author":"Schmier JK","year":"2014","journal-title":"BMC Public Health"},{"key":"ref7","doi-asserted-by":"crossref","first-page":"A365","DOI":"10.1016\/j.jval.2014.08.815","article-title":"Health care cost associated to constipation predominant irritable bowel syndrome in Spain","volume":"17","author":"Raya A","year":"2014","journal-title":"Value Heal"},{"key":"ref8","doi-asserted-by":"crossref","first-page":"S78","DOI":"10.1016\/j.jval.2011.05.019","article-title":"Health care resource use and costs in opioid-treated patients with and without constipation in Brazil","volume":"14","author":"Takemoto MLS","year":"2011","journal-title":"Value Health"},{"key":"ref9","doi-asserted-by":"crossref","first-page":"86","DOI":"10.5694\/mja18.00241","article-title":"Chronic idiopathic constipation in adults: epidemiology, pathophysiology, diagnosis and clinical management","volume":"Vol. 209","author":"Black CJ","year":"2018","journal-title":"Medical Journal of Australia"},{"key":"ref10","first-page":"S55","article-title":"Update on the management of chronic idiopathic constipation","volume":"25","author":"Lacy BE","year":"2019","journal-title":"Am J Manag Care"},{"key":"ref11","doi-asserted-by":"crossref","first-page":"111","DOI":"10.1016\/j.sjpain.2015.12.005","article-title":"Definition, diagnosis and treatment strategies for opioid-induced bowel dysfunction-Recommendations of the Nordic Working Group","volume":"11","author":"Drewes AM","year":"2016","journal-title":"Scand J Pain"},{"key":"ref12","article-title":"Bowel disorders","volume":"150","author":"Lacy BE","year":"2016","journal-title":"Gastroenterology"},{"key":"ref13","doi-asserted-by":"crossref","DOI":"10.1016\/j.cgh.2012.02.029","article-title":"Global Prevalence of and Risk Factors for Irritable Bowel Syndrome: A Meta-analysis","volume":"10","author":"Lovell RM","year":"2012","journal-title":"Clin Gastroenterol Hepatol"},{"key":"ref14","doi-asserted-by":"crossref","first-page":"35","DOI":"10.1111\/j.1526-4637.2008.00495.x","article-title":"The Prevalence, Severity, and Impact of Opioid-Induced Bowel Dysfunction: Results of a US and European Patient Survey (PROBE 1)","volume":"10","author":"Bell TJ","year":"2009","journal-title":"Pain Med"},{"key":"ref15","doi-asserted-by":"crossref","first-page":"697","DOI":"10.1111\/j.1365-2982.2011.01709.x","article-title":"Diagnosis and treatment of chronic constipation--a European perspective","volume":"23","author":"Tack J","year":"2011","journal-title":"Neurogastroenterol Motil"},{"key":"ref16","doi-asserted-by":"crossref","first-page":"899","DOI":"10.1185\/03007995.2016.1150262","article-title":"Treatment patterns, symptom reduction, quality of life, and resource use associated with lubiprostone in irritable bowel syndrome constipation subtype","volume":"32","author":"Solem CT","year":"2016","journal-title":"Curr Med Res Opin"},{"key":"ref17","doi-asserted-by":"crossref","first-page":"383","DOI":"10.5056\/jnm15185","article-title":"Guidelines for the Diagnosis and Treatment of Chronic Functional Constipation in Korea, 2015 Revised Edition","volume":"22","author":"Shin JE","year":"2016","journal-title":"J Neurogastroenterol Motil"},{"key":"ref18","series-title":"Therapeutic Advances in Chronic Disease","first-page":"40","volume-title":"Lubiprostone in constipation: Clinical evidence and place in therapy","volume":"Vol. 6","author":"Wilson N","year":"2015"},{"key":"ref19","doi-asserted-by":"crossref","first-page":"1090","DOI":"10.1007\/s10620-009-1068-x","article-title":"Efficacy and Safety of Lubiprostone in Patients with Chronic Constipation","volume":"55","author":"Barish CF","year":"2010","journal-title":"Dig Dis Sci"},{"key":"ref20","doi-asserted-by":"crossref","DOI":"10.1111\/j.1365-2982.2011.01668.x","article-title":"Efficacy and safety of oral lubiprostone in constipated patients with or without irritable bowel syndrome: a randomized, placebo-controlled and dose-finding study","volume":"23","author":"Fukudo S","year":"2011","journal-title":"Neurogastroenterol Motil"},{"key":"ref21","doi-asserted-by":"crossref","first-page":"1825","DOI":"10.1111\/pme.12437","article-title":"A Randomized Study of Lubiprostone for Opioid-Induced Constipation in Patients with Chronic Noncancer Pain","volume":"15","author":"Cryer B","year":"2014","journal-title":"Pain Med"},{"key":"ref22","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pone.0175626","article-title":"Lubiprostone improves intestinal permeability in humans, a novel therapy for the leaky gut: A prospective randomized pilot study in healthy volunteers","volume":"12","author":"Kato T","year":"2017","journal-title":"PLoS One"},{"key":"ref23","doi-asserted-by":"crossref","first-page":"133","DOI":"10.1186\/s12876-016-0542-0","article-title":"Addition of Lubiprostone to polyethylene glycol (PEG) enhances the quality and efficacy of colonoscopy preparation: a randomized, double-blind, placebo controlled trial","volume":"16","author":"Banerjee R","year":"2016","journal-title":"BMC Gastroenterol"},{"key":"ref24","doi-asserted-by":"crossref","first-page":"105","DOI":"10.1097\/MJT.0b013e31826b7a1f","article-title":"Lubiprostone Plus PEG Electrolytes Versus Placebo Plus PEG Electrolytes for Outpatient Colonoscopy Preparation","volume":"22","author":"Sofi AA","year":"2015","journal-title":"Am J Ther"},{"key":"ref25","doi-asserted-by":"crossref","first-page":"456","DOI":"10.1016\/j.mayocp.2016.01.015","article-title":"Lubiprostone Is Effective in the Treatment of Chronic Idiopathic Constipation and Irritable Bowel Syndrome: A Systematic Review and Meta-Analysis of Randomized Controlled Trials","volume":"91","author":"Li F","year":"2016","journal-title":"Mayo Clin Proc"},{"key":"ref26","doi-asserted-by":"crossref","first-page":"d5928","DOI":"10.1136\/bmj.d5928","article-title":"The Cochrane Collaboration\u2019s tool for assessing risk of bias in randomised trials","volume":"343","author":"Higgins JPT","year":"2011","journal-title":"BMJ"},{"key":"ref27","doi-asserted-by":"crossref","first-page":"1650","DOI":"10.1212\/WNL.0b013e3182574f28","article-title":"Placebo-controlled trial of lubiprostone for constipation associated with Parkinson disease","volume":"78","author":"Ondo WG","year":"2012","journal-title":"Neurology"},{"key":"ref28","doi-asserted-by":"crossref","first-page":"16323","DOI":"10.3748\/wjg.v20.i43.16323","article-title":"Lubiprostone vs Senna in postoperative orthopedic surgery patients with opioid-induced constipation: A double-blind, active-comparator trial","volume":"20","author":"Marciniak CM","year":"2014","journal-title":"World J Gastroenterol"},{"key":"ref29","doi-asserted-by":"crossref","first-page":"685","DOI":"10.1111\/j.1365-2036.2008.03629.x","article-title":"Clinical trial: phase 2 study of lubiprostone for irritable bowel syndrome with constipation","volume":"27","author":"Johanson JF","year":"2008","journal-title":"Aliment Pharmacol Ther"},{"key":"ref30","doi-asserted-by":"crossref","first-page":"356","DOI":"10.1038\/ajg.2016.531","article-title":"A Randomized, Double-Blind, Placebo-Controlled Trial to Examine the Effectiveness of Lubiprostone on Constipation Symptoms and Colon Transit Time in Diabetic Patients","volume":"112","author":"Christie J","year":"2017","journal-title":"Am J Gastroenterol"},{"key":"ref31","doi-asserted-by":"crossref","DOI":"10.1016\/j.cgh.2014.08.026","article-title":"Lubiprostone Increases Spontaneous Bowel Movement Frequency and Quality of Life in Patients With Chronic Idiopathic Constipation","volume":"13","author":"Fukudo S","year":"2015","journal-title":"Clin Gastroenterol Hepatol"},{"key":"ref32","doi-asserted-by":"crossref","first-page":"170","DOI":"10.1111\/j.1572-0241.2007.01524.x","article-title":"Multicenter, 4-Week, Double-Blind, Randomized, Placebo-Controlled Trial of Lubiprostone, a Locally-Acting Type-2 Chloride Channel Activator, in Patients With Chronic Constipation","volume":"103","author":"Johanson JF","year":"2008","journal-title":"Am J Gastroenterol"},{"key":"ref33","doi-asserted-by":"crossref","first-page":"329","DOI":"10.1111\/j.1365-2036.2008.03881.x","article-title":"Clinical trial: lubiprostone in patients with constipation-associated irritable bowel syndrome - results of two randomized, placebo-controlled studies","volume":"29","author":"Drossman DA","year":"2009","journal-title":"Aliment Pharmacol Ther"},{"key":"ref34","doi-asserted-by":"crossref","first-page":"3568","DOI":"10.1007\/s10620-017-4680-1","article-title":"Analysis of Nausea in Clinical Studies of Lubiprostone for the Treatment of Constipation Disorders","volume":"62","author":"Cryer B","year":"2017","journal-title":"Dig Dis Sci"},{"key":"ref35","doi-asserted-by":"crossref","first-page":"312","DOI":"10.1111\/papr.12444","article-title":"Lubiprostone for Opioid-Induced Constipation Does Not Interfere with Opioid Analgesia in Patients with Chronic Noncancer Pain","volume":"17","author":"Spierings ELH","year":"2017","journal-title":"Pain Pract"},{"key":"ref36","doi-asserted-by":"crossref","first-page":"725","DOI":"10.1038\/ajg.2015.106","article-title":"A Randomized, Placebo-Controlled Trial of Lubiprostone for Opioid-Induced Constipation in Chronic Noncancer Pain","volume":"110","author":"Jamal MM","year":"2015","journal-title":"Am J Gastroenterol"},{"key":"ref37","doi-asserted-by":"crossref","first-page":"1114","DOI":"10.1111\/apt.13807","article-title":"Effects of baseline abdominal pain and bloating on response to lubiprostone in patients with irritable bowel syndrome with constipation","volume":"44","author":"Chang L","year":"2016","journal-title":"Aliment Pharmacol Ther"},{"key":"ref38","doi-asserted-by":"crossref","first-page":"1351","DOI":"10.1111\/j.1365-2036.2007.03320.x","article-title":"Lubiprostone, a locally acting chloride channel activator, in adult patients with chronic constipation: a double-blind, placebo-controlled, dose-ranging study to evaluate efficacy and safety","volume":"25","author":"Johanson JF","year":"2007","journal-title":"Aliment Pharmacol Ther"},{"key":"ref39","doi-asserted-by":"crossref","first-page":"1184","DOI":"10.1093\/pm\/pnx156","article-title":"Efficacy and Safety of Lubiprostone in Patients with Opioid-Induced Constipation: Phase 3 Study Results and Pooled Analysis of the Effect of Concomitant Methadone Use on Clinical Outcomes","volume":"19","author":"Spierings ELH","year":"2018","journal-title":"Pain Med"},{"key":"ref40","doi-asserted-by":"crossref","first-page":"456","DOI":"10.1016\/j.mayocp.2016.01.015","article-title":"Lubiprostone Is Effective in the Treatment of Chronic Idiopathic Constipation and Irritable Bowel Syndrome","volume":"91","author":"Li F","year":"2016","journal-title":"Mayo Clin Proc"},{"key":"ref41","doi-asserted-by":"crossref","first-page":"587","DOI":"10.1111\/j.1365-2036.2011.04983.x","article-title":"Safety and patient outcomes with lubiprostone for up to 52 weeks in patients with irritable bowel syndrome with constipation","volume":"35","author":"Chey WD","year":"2012","journal-title":"Aliment Pharmacol Ther"},{"key":"ref42","doi-asserted-by":"crossref","first-page":"2639","DOI":"10.1007\/s10620-011-1801-0","article-title":"Long-Term Safety and Effectiveness of Lubiprostone, a Chloride Channel (ClC-2) Activator, in Patients with Chronic Idiopathic Constipation","volume":"56","author":"Lembo AJ","year":"2011","journal-title":"Dig Dis Sci"},{"key":"ref43","doi-asserted-by":"crossref","first-page":"495","DOI":"10.1038\/nrurol.2011.99","article-title":"The placebo effect in overactive bladder syndrome","volume":"8","author":"Mangera A","year":"2011","journal-title":"Nat Rev Urol"},{"key":"ref44","doi-asserted-by":"crossref","DOI":"10.1016\/j.bja.2019.01.040","article-title":"Pain, placebo, and test of treatment efficacy: a narrative review","volume":"123","author":"Vase L","year":"2019","journal-title":"Br J Anaesth"},{"key":"ref45","doi-asserted-by":"crossref","first-page":"18","DOI":"10.1016\/j.jclinepi.2016.12.010","article-title":"Sham surgical procedures for pain intervention result in significant improvements in pain: systematic review and meta-analysis","volume":"83","author":"Gu AP","year":"2017","journal-title":"J Clin Epidemiol"}],"container-title":["Arquivos de Gastroenterologia"],"original-title":[],"link":[{"URL":"http:\/\/www.scielo.br\/pdf\/ag\/v57n4\/1678-4219-ag-57-04-498.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2021,1,24]],"date-time":"2021-01-24T02:16:10Z","timestamp":1611454570000},"score":1,"resource":{"primary":{"URL":"http:\/\/www.scielo.br\/scielo.php?script=sci_arttext&pid=S0004-28032020000400498&tlng=en"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2020,12]]},"references-count":45,"journal-issue":{"issue":"4","published-online":{"date-parts":[[2020,12]]}},"alternative-id":["S0004-28032020000400498"],"URL":"https:\/\/doi.org\/10.1590\/s0004-2803.202000000-83","relation":{},"ISSN":["1678-4219","0004-2803"],"issn-type":[{"type":"electronic","value":"1678-4219"},{"type":"print","value":"0004-2803"}],"subject":[],"published":{"date-parts":[[2020,12]]}}}